Number of Participants Who Could Tolerate Twice Daily Oxytocin
| Group | Value (Participants) |
|---|---|
| Sequence 2: Placebo:Oxytocin | 13 |
| Sequence 1: Oxytocin:Oxytocin | 11 |
Trial · Interventional
CompletedPhase 2Results postedRegistry dataShort name Oxytocin
United States
1 trial · 1 completed · 1 with posted results
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
The investigators propose to conduct this pilot study to evaluate oxytocin as a supplemental treatment for improving social difficulties in individuals with autism.
Placebo comparator
Placebo
Intervention: Drug: placebo
Active comparator
Oxytocin
Intervention: Drug: Syntocinon® Nasal Spray
Outcomes the sponsor listed as primary.
Number of Participants Who Could Tolerate Twice Daily Oxytocin
Time frame · Week 0 to week 8
This study will help to determine tolerability of intranasal oxytocin treatment in children with autism by measuring the ability of at least 80% of the sample to tolerate twice daily intranasal administration of oxytocin.
Number of Participants Who Could Tolerate Twice Daily Oxytocin
Time frame · Week 0 to week 16
This study will help to determine tolerability of intranasal oxytocin treatment in children with autism by measuring the ability of at least 80% of the sample to tolerate twice daily intranasal administration of oxytocin.
Change in Mean Plasma Oxytocin Level During Period 1 - Double Blind Phase
Time frame · Week 0 to week 8
Blood samples will be collected to obtain proof of concept data regarding changes in afternoon plasma oxytocin levels
Change in Mean Weight
Time frame · between weeks 0 and 8
changes during period 1
Change in Mean Total Social Social Responsiveness Scale (SRS) T-score
Time frame · 0-8 weeks, blinded treatment, period 1
The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The raw score of each individual item is summed to create a total raw score. The total raw score is then translated into a total T-scores (which are the equivalent of standard scores). Total T-scores results are as follows: 59 and below: within normal limits, 60-65: Mild range of impairment 66-75: Moderate range of impairment 76 or higher: Severe range of impairment.
Change in Mean Autism Diagnostic Observation Schedule (ADOS) Total Score
Time frame · Baseline to 16 Weeks
The ADOS is a semi-structured assessment used to assess and diagnose individuals suspected of having autism of varying ages, developmental levels, and language skills (from no speech to verbally fluent). The ADOS includes four modules, each requiring just 35-40 minutes to administer. The individual being evaluated is given just one of 4 modules, depending on his or her expressive language level and chronological age. The rater will observe social and communication behaviors during various activities in the appropriate module. A rater then uses a 0-3 scale to rate each type of behavior. A select number of individual items will be summed for a total score representing communication and reciprocal social interaction. In scoring all 3's are collapsed to a 2. A higher score indicates more severe impairment. Ranges of scores are as follows: Module 1: 0-24, Module 2: 0-24, Module 3: 0-22, Module 4: 0-22.
Change in Mean Aberrant Behavior Checklist (ABC)-Social Withdrawal Subscale Score Over Both Periods
Time frame · Baseline to 16 Weeks
Efficacy measures included the Aberrant Behavior Checklist -Social Withdrawal subscale scor. The ABC which focuses on problem behaviors in five subdomains, including irritability, attention, repetitive behaviors, unusual speech, and lethargy. A modified version of the lethargy subscale was used. Typically the Lethargy subscale includes 16 items, however, for our purposes 3 items that were specifically related to lethargy (i.e.: listlessness) were removed so that the focus could primarily be on aberrant social behavior. Differences in only the Social Withdrawal domain were assessed.The is the sum of items, each rated among 0 = Not at all; 1 = Slight in degree; 2 = Moderately serious; and 3 = Severe in degree. The ABC- Social Withdrawal total score ranges from 0 to 39. Higher values represent greater severity of illness.
Change in Mean Pervasive Developmental Disorder Behavior Inventory - Screening Version (PDDBI-SV) Total Score Over Both Periods
Time frame · Baseline to 16 Weeks
The PDDBI-SV examines both adaptive and maladaptive behaviors related to autism. It has normative scores for children between 2-11 years. For children 12 years and older, the norms (11 years, 11 months) will be used. Each item is scored on a scale from 0-3. For the first 9 items, the total of individual items is summed. For items 10-18, the scores are reversed and then summed (i.e.: 0=3, 1 =2, 2=2, 3 = 0). Then the total of 0-9 and then the reversed scored items 10-18 are summed for a final total score. Higher scores indicate more impairment. The range of total scores is 0-54. ASD/Social deficits unlikely: 0-6, More information needed/borderline: 7-10, autism spectrum disorder (ASD)/social deficits likely (mild):11-14, ASD/social deficits likely (moderate): 15-29, ASD/social deficits likely (severe): 30-37, ASD/social deficits likely (extreme): 38 or higher.
Change in Mean Systolic Blood Pressure During Period 1
Time frame · Week 0 to 8
Change in mean systolic blood pressure during double blind phase
Mean Change in Prolactin Levels Over Period 1
Time frame · Week 0 to 8
Serum prolactin levels were collected and analyzed in participants
Mean Change in Temperature During Period 1
Time frame · Week 0 to 8
Temperature was collected on each participant via oral or temporal thermometer. The mean change in each group was assessed.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (Participants) |
|---|---|
| Sequence 2: Placebo:Oxytocin | 13 |
| Sequence 1: Oxytocin:Oxytocin | 11 |
| Group | Value (Participants) |
|---|---|
| Sequence 2: Placebo:Oxytocin | 11 |
| Sequence 2: Oxytocin:Oxytocin | 11 |
| Group | Value (picograms/mL (pg/mL)) | Spread |
|---|---|---|
| Sequence 2: Placebo:Oxytocin | -0.69 | 1.69 |
| Sequence 1: Oxytocin:Oxytocin | -0.15 | 1.53 |
| Group | Value (pounds) | Spread |
|---|---|---|
| Sequence 1: Oxytocin-oxytocin | 1.4 | 1.3 |
| Sequence 2: Placebo :Oxytocin | 2.4 | 0.7 |
| Group | Value (T-scores) | Spread |
|---|---|---|
| Sequence 1: Oxytocin-oxytocin | -5.1 | 2.3 |
| Sequence 2: Placebo :Oxytocin | -3.9 | 3.3 |
| Group | Value (scores on a scale) | Spread |
|---|---|---|
| Sequence 1: Oxytocin-oxytocin | -0.36 | 0.39 |
| Sequence 2: Placebo :Oxytocin | -0.31 | 0.29 |
| Group | Value (scores on a scale) | Spread |
|---|---|---|
| Sequence 1: Oxytocin-oxytocin | -3.7 | 1.0 |
| Sequence 2: Placebo :Oxytocin | -2.2 | 1.9 |
| Group | Value (scores on a scale) | Spread |
|---|---|---|
| Sequence 1: Oxytocin-oxytocin | -3.6 | 2.4 |
| Sequence 2: Placebo :Oxytocin | -3.0 | 2.2 |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Sequence 1: Oxytocin:Oxytocin Period 1weeks 0-8Intervention: Drug: Syntocinon® Nasal Spray Oxytocin: Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase. Subjects ages 3-10 years old will be titrated up to a maximum dose of 24IU. Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU. | 0 / 12 | 1 / 12 | 12 / 12 |
| Sequence 2: Placebo: Oxytocin Period 1 Weeks 0-8Intervention: Drug: placebo Placebo: Placebo Nasal Spray | 0 / 13 | 0 / 13 | 10 / 13 |
| Sequence 1: Oxytocin:Oxytocin Period 2, Weeks 8-16evaluates longer term adverse events with oxytocin | 0 / 11 | 0 / 24 | 8 / 11 |
| Sequence 2: Placebo:Oxytocin Period 2evaluates acute exposure to oxytocin in sequence 2 participants | 0 / 13 | 0 / 13 | 12 / 13 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
No study cites this trial.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated